Results 161 to 170 of about 11,087,757 (202)
Some of the next articles are maybe not open access.
DPP-4 inhibitors: a patent review (2012 – 2014)
Expert Opinion on Therapeutic Patents, 2014Dipeptidyl peptidase 4 (DPP-4) is a serine protease, which catalyzes the hydrolytic process of the amide bond X-Ala or X-Pro at the N-terminus of peptides. This enzyme is involved in the degradation of two incretin hormones glucagon-like peptide-1 and glucose-dependent-insulinotropic polypeptide, which increase the production and release of insulin ...
COSTANTE, ROBERTO +4 more
openaire +3 more sources
DPP-4 inhibitors: pharmacological differences and their clinical implications
Expert Opinion on Drug Safety, 2014Recently, incretin-based therapy was introduced for the treatment of type 2 diabetes (T2D). In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D.An extensive literature search was performed to analyze the pharmacological ...
Ceriello A +3 more
openaire +2 more sources
Wildagliptyna - wyjątkowy inhibitor DPP-4
Medycyna Faktów, 2022Wildagliptyna jest jedynym lekiem z grupy inhibitorów DPP-4, który stosuje się 2 razy dziennie. Chociaż nie przeprowadzono badania poświęconego bezpieczeństwu sercowo-naczyniowemu stosowania tego leku, to licznie opublikowane metaanalizy oraz badania obserwacyjne jednoznacznie potwierdziły bezpieczeństwo wildagliptyny w tym zakresie.
openaire +2 more sources
How safe are DPP‐4 inhibitors?
Practical Diabetes, 2013AbstractAbstract.
Laura McCreight, Miles Fisher
openaire +1 more source
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Archives of Pharmacal Research, 2016Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are an emerging class of antidiabetic drugs that constitutes approximately fifty percent of the market share of the oral hypoglycemic drugs. Its mechanism of action for lowering blood glucose is essentially via inhibition of the rapid degradation of incretin hormones, such as glucagon-like peptide ...
openaire +2 more sources
Inappropriate Use of DPP-4 Inhibitors
2014Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents for the treatment of type 2 diabetes. They have shown reduction of blood glucose, but potential impact on cardiovascular outcomes and long-term safety remain inconclusive. For that reasons DPP-4[for full text, please go to the a.m. URL]
Reichel, A +4 more
openaire +1 more source
[DPP-4 inhibitors in nephropatics].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologiaThe use of glucose-lowering drugs in advanced stage diabetic nephropathic patients should be done very carefully. Some drugs are contraindicated or not recommended. The same insulin needs a dose reduction to avoid dangerous hypoglycemia. For some years the use of inhibitors of the DDP-4 has been approved in T2DM patients with CKD III and IV stage ...
Annamaria, Bruzzese +4 more
openaire +1 more source
DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema
Journal of Investigative Medicine High Impact Case Reports, 2021Chidinma Ejikeme
exaly